Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025

Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in…

SNAP Biosciences licenses Monarch's cell therapy tech

SNAP Biosciences licenses Monarch's cell therapy tech#SNAP #Biosciences #licenses #Monarch039s #cell #therapy #tech

Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX);

Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO…

Castle Biosciences amends charter, stockholders vote

Castle Biosciences amends charter, stockholders vote#Castle #Biosciences #amends #charter #stockholders #vote

Arcus Biosciences Stock May Be The Next To Fail (NYSE:RCUS)

This article was written by Follow At ELAM1, we empower financial professionals and investors with the…

Cytek Biosciences, Inc. (CTKB) Q1 2025 Earnings Call Transcript

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company…

Pulse Biosciences, Inc. (PLSE) Q1 2025 Earnings Call Transcript

Pulse Biosciences, Inc. (PLSE) Q1 2025 Earnings Call Transcript #Pulse #Biosciences #PLSE #Earnings #Call #Transcript

WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS

WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS#WILLOW #BIOSCIENCES #ANNOUNCES #ANNUAL #GENERAL #SPECIAL #MEETING…

Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025

Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025 #Neurocrine #Biosciences #Valbenazine #Adjunctive #Therapy…

Aura Biosciences executive sells $39,319 in stock

Aura Biosciences executive sells $39,319 in stock#Aura #Biosciences #executive #sells #stock

Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity

Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity #Neurocrine #Biosciences #Selloff #Created #Potential #Buying…

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later #Ideaya #Biosciences #Prices…

Genflow Biosciences enters AI gene therapy research deal

Genflow Biosciences enters AI gene therapy research deal#Genflow #Biosciences #enters #gene #therapy #research #deal

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space #Solid #Biosciences…

Does Colossal Biosciences’ dire wolf creation justify its $10B+ valuation?

On Monday, the “de-extinction” startup Colossal Biosciences announced its most ambitious results to date: the dire…

Ventyx Biosciences chief scientific officer John Nuss sells $2,019 in shares

Ventyx Biosciences chief scientific officer John Nuss sells $2,019 in shares#Ventyx #Biosciences #chief #scientific #officer #John…

Ideaya Biosciences stock hits 52-week low at $16.95

Ideaya Biosciences stock hits 52-week low at $16.95#Ideaya #Biosciences #stock #hits #52week

Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript

Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript #Pulse #Biosciences #PLSE #Earnings #Call #Transcript

Junshi Biosciences Announces Toripalimab's Approval in Singapore

Junshi Biosciences Announces Toripalimab's Approval in Singapore#Junshi #Biosciences #Announces #Toripalimab039s #Approval #Singapore

Harmony Biosciences: A Compelling Risk-Reward Opportunity

Harmony Biosciences: A Compelling Risk-Reward Opportunity #Harmony #Biosciences #Compelling #RiskReward #Opportunity

Pacira BioSciences: Back On An Uptrend After Positive Developments

Pacira BioSciences: Back On An Uptrend After Positive Developments #Pacira #BioSciences #Uptrend #Positive #Developments

PCRX IMPORTANT DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Secu

PCRX IMPORTANT DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Pacira BioSciences, Inc. Investors with Losses…